KR102537091B1 - 클라우딘 발현 암 질환을 치료하기 위한 클라우딘6 또는 클라우딘18.2 및 cd3에 결합하는 이중특이적 3가 항체 - Google Patents

클라우딘 발현 암 질환을 치료하기 위한 클라우딘6 또는 클라우딘18.2 및 cd3에 결합하는 이중특이적 3가 항체 Download PDF

Info

Publication number
KR102537091B1
KR102537091B1 KR1020197008288A KR20197008288A KR102537091B1 KR 102537091 B1 KR102537091 B1 KR 102537091B1 KR 1020197008288 A KR1020197008288 A KR 1020197008288A KR 20197008288 A KR20197008288 A KR 20197008288A KR 102537091 B1 KR102537091 B1 KR 102537091B1
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
cancer
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197008288A
Other languages
English (en)
Korean (ko)
Other versions
KR20190052002A (ko
Inventor
우르 사힌
크리스티안 슈타들러
레일라 피셔
아르네 젠드레츠키
오즈렘 튀게시
파브리스 리 갈
마리아 크로이츠베르그
Original Assignee
비온테크 에스이
아스테라스 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비온테크 에스이, 아스테라스 세이야쿠 가부시키가이샤 filed Critical 비온테크 에스이
Priority to KR1020237017307A priority Critical patent/KR20230074637A/ko
Publication of KR20190052002A publication Critical patent/KR20190052002A/ko
Application granted granted Critical
Publication of KR102537091B1 publication Critical patent/KR102537091B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197008288A 2016-09-23 2017-09-20 클라우딘 발현 암 질환을 치료하기 위한 클라우딘6 또는 클라우딘18.2 및 cd3에 결합하는 이중특이적 3가 항체 Active KR102537091B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237017307A KR20230074637A (ko) 2016-09-23 2017-09-20 클라우딘 발현 암 질환을 치료하기 위한 클라우딘6 또는 클라우딘18.2 및 cd3에 결합하는 이중특이적 3가 항체

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/072688 WO2018054484A1 (en) 2016-09-23 2016-09-23 Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
EPPCT/EP2016/072688 2016-09-23
PCT/EP2017/073773 WO2018054973A1 (en) 2016-09-23 2017-09-20 Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017307A Division KR20230074637A (ko) 2016-09-23 2017-09-20 클라우딘 발현 암 질환을 치료하기 위한 클라우딘6 또는 클라우딘18.2 및 cd3에 결합하는 이중특이적 3가 항체

Publications (2)

Publication Number Publication Date
KR20190052002A KR20190052002A (ko) 2019-05-15
KR102537091B1 true KR102537091B1 (ko) 2023-05-31

Family

ID=57003498

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197008288A Active KR102537091B1 (ko) 2016-09-23 2017-09-20 클라우딘 발현 암 질환을 치료하기 위한 클라우딘6 또는 클라우딘18.2 및 cd3에 결합하는 이중특이적 3가 항체
KR1020237017307A Ceased KR20230074637A (ko) 2016-09-23 2017-09-20 클라우딘 발현 암 질환을 치료하기 위한 클라우딘6 또는 클라우딘18.2 및 cd3에 결합하는 이중특이적 3가 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237017307A Ceased KR20230074637A (ko) 2016-09-23 2017-09-20 클라우딘 발현 암 질환을 치료하기 위한 클라우딘6 또는 클라우딘18.2 및 cd3에 결합하는 이중특이적 3가 항체

Country Status (14)

Country Link
US (2) US11787862B2 (https=)
EP (2) EP4043494A1 (https=)
JP (3) JP7055794B2 (https=)
KR (2) KR102537091B1 (https=)
CN (2) CN118388656A (https=)
AU (3) AU2017331331B2 (https=)
BR (1) BR112019002168A2 (https=)
CA (1) CA3034186A1 (https=)
IL (3) IL264233B (https=)
MX (2) MX2019003350A (https=)
NZ (1) NZ750132A (https=)
SG (1) SG11201901899PA (https=)
WO (2) WO2018054484A1 (https=)
ZA (2) ZA201900962B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024258238A1 (ko) * 2023-06-15 2024-12-19 에이비온 주식회사 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
CN111867630B (zh) 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
US11505618B2 (en) * 2018-07-18 2022-11-22 Askgene Pharma Inc. Antibodies and methods for making and using the same
JOP20210022A1 (ar) * 2018-08-03 2021-01-28 Amgen Inc بنيات جسم مضاد لـ cldn18.2وcd3
JP7458399B2 (ja) * 2018-12-07 2024-03-29 ゼットリップ ホールディング リミテッド 抗クローディン抗体及びそれらの使用
US12297265B2 (en) 2018-12-28 2025-05-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody and use thereof
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US20220127372A1 (en) * 2019-02-01 2022-04-28 Cafa Therapeutics Limited Tcr fusion protein and cell expressing tcr fusion protein
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
US20220184126A1 (en) * 2019-03-29 2022-06-16 Phanes Therapeutis, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
KR102239781B1 (ko) * 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
CN117659190A (zh) * 2019-05-16 2024-03-08 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
CR20220049A (es) * 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Moléculas de unión a claudina-6 y usos de las mismas
JP2022541435A (ja) * 2019-07-17 2022-09-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン１８抗体及びがんを処置する方法
PE20211147A1 (es) 2019-08-12 2021-06-28 I Mab Biopharma Us Ltd Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso
CA3174094A1 (en) * 2020-03-31 2021-10-07 Shinya Ishii Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
US20230192903A1 (en) * 2020-05-29 2023-06-22 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody against cldn18.2 and cd3
CN115943162A (zh) * 2020-06-19 2023-04-07 信达生物制药(苏州)有限公司 抗Claudin18.2抗体以及其用途
US20230322953A1 (en) * 2020-06-30 2023-10-12 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
CN114106195B (zh) * 2020-08-27 2024-09-17 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
KR20230079165A (ko) * 2020-09-29 2023-06-05 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항-클라우딘18.2 및 cd3 이특이적 항체 및 이의 용도
AU2021374036A1 (en) * 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
KR20230107305A (ko) * 2020-11-10 2023-07-14 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
CN114853897B (zh) * 2021-04-15 2024-01-26 北京大学深圳研究生院 抗cd19/cd22/cd3三特异性抗体及用途
JP7734994B2 (ja) * 2021-06-02 2025-09-08 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗ｃｄ３抗体変異体、融合タンパク質および適用
JP2024523166A (ja) * 2021-06-15 2024-06-28 ゼンコア インコーポレイテッド クローディン１８．２及びｃｄ３に結合するヘテロ二量体抗体
WO2022262959A1 (en) * 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3
AU2022311053A1 (en) * 2021-07-15 2023-12-14 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
US20240344030A1 (en) * 2021-07-28 2024-10-17 Cartesian Therapeutics, Inc. Multiprotein-engineered cells secreting a multispecific antibody
US20250297005A1 (en) * 2022-03-28 2025-09-25 Fortvita Biologics (Singapore) Pte. Ltd. Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof
WO2023206242A1 (zh) * 2022-04-28 2023-11-02 江苏中新医药有限公司 无钩状效应的抗人cd73单克隆抗体
CA3256593A1 (en) * 2022-06-01 2023-12-07 Integral Molecular, Inc. Claudine antibodies 18.2, their manufacturing processes and their uses
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
KR20250120305A (ko) * 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
AR132063A1 (es) * 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
CN116087069B (zh) * 2023-04-10 2023-08-08 苏州药明康德新药开发有限公司 一种基于流式细胞术检测特定细胞群体组蛋白甲基化和乙酰化修饰水平的方法
WO2024243093A2 (en) * 2023-05-19 2024-11-28 The Regents Of The University Of California Multispecific antibodies targeting cd3 and cd22
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
AR134560A1 (es) * 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120866A1 (en) * 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
WO2025231017A1 (en) * 2024-04-30 2025-11-06 Context Therapeutics Inc. Bispecific antibodies and methods of using the same
WO2025231015A1 (en) * 2024-04-30 2025-11-06 Context Therapeutics Inc. Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2015113576A1 (en) 2014-01-29 2015-08-06 Biontech Ag Peptide mimotopes of claudin 18.2 and uses thereof
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2016097408A1 (en) * 2014-12-19 2016-06-23 Biotecnol Limited Fusion protein comprising three binding domains to 5t4 and cd3

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
CN1326881C (zh) 2003-09-29 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 一种三价双特异性抗体，其制备方法及用途
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2014075788A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US9605084B2 (en) * 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
WO2016135239A1 (en) 2015-02-25 2016-09-01 Biotecnol Limited Fusion protein comprising three binding domains to her2
WO2022262959A1 (en) * 2021-06-15 2022-12-22 Astellas Pharma Europe Bv Bispecific binding agents binding to cldn18.2 and cd3

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2015113576A1 (en) 2014-01-29 2015-08-06 Biontech Ag Peptide mimotopes of claudin 18.2 and uses thereof
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2016097408A1 (en) * 2014-12-19 2016-06-23 Biotecnol Limited Fusion protein comprising three binding domains to 5t4 and cd3

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024258238A1 (ko) * 2023-06-15 2024-12-19 에이비온 주식회사 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도

Also Published As

Publication number Publication date
AU2017331331B2 (en) 2022-03-10
JP7436552B2 (ja) 2024-02-21
US20240158501A1 (en) 2024-05-16
IL290230A (en) 2022-03-01
EP3515939A1 (en) 2019-07-31
JP2019535234A (ja) 2019-12-12
US11787862B2 (en) 2023-10-17
IL264233B (en) 2022-03-01
CN110023336A (zh) 2019-07-16
BR112019002168A2 (pt) 2019-09-17
WO2018054484A1 (en) 2018-03-29
CN118388656A (zh) 2024-07-26
JP2024054250A (ja) 2024-04-16
MX2023005375A (es) 2023-05-22
KR20190052002A (ko) 2019-05-15
RU2019112165A (ru) 2020-10-23
CA3034186A1 (en) 2018-03-29
IL264233A (en) 2019-02-28
CN110023336B (zh) 2024-05-17
NZ750132A (en) 2023-05-26
AU2022200283A1 (en) 2022-02-17
ZA202002471B (en) 2021-09-29
US20190309067A1 (en) 2019-10-10
EP4043494A1 (en) 2022-08-17
IL290234A (en) 2022-03-01
AU2025202697A1 (en) 2025-05-08
SG11201901899PA (en) 2019-04-29
AU2017331331A1 (en) 2019-02-07
MX2019003350A (es) 2019-08-12
ZA201900962B (en) 2020-10-28
RU2019112165A3 (https=) 2021-01-20
KR20230074637A (ko) 2023-05-30
AU2022200283A2 (en) 2022-04-21
WO2018054973A1 (en) 2018-03-29
JP7791916B2 (ja) 2025-12-24
JP2022091973A (ja) 2022-06-21
JP7055794B2 (ja) 2022-04-18

Similar Documents

Publication Publication Date Title
JP7436552B2 (ja) クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体
US20240228616A1 (en) Agents for Treatment of Claudin Expressing Cancer Diseases
EP2920209B1 (en) Agents for treatment of claudin expressing cancer diseases
KR20240032847A (ko) Cldn18.2 및 cd3에 결합하는 이중특이 결합제
RU2798988C2 (ru) Биспецифические трехвалентные антитела, связывающиеся с клаудином 6 или клаудином 18.2, и cd3, для лечения онкологических заболеваний с экспрессией клаудина
HK40078730A (en) Bispecific trivalent antibodies binding to claudin 6 or claudin 18.2 and cd3 for treatment of claudin expressing cancer diseases
HK40010154B (zh) 用於治疗表达密蛋白之癌症疾病的与密蛋白6或密蛋白18 .2和cd3结合的双特异性三价抗体
NZ792363A (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
HK40043784A (en) Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190321

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200916

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220718

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230223

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230522

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230523

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230524

End annual number: 3

Start annual number: 1

PG1601 Publication of registration